Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $51.29 +4.97%
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
COHR, ATS, SICP, More
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25).
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Progyny (PGNY) Tops Q3 EPS by 21c ; Offers Guidance
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
- Power Integrations (POWI) Tops Q3 EPS by 5c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
